Alzamend Neuro (ALZN) Net Cash Flow (2020 - 2026)

Alzamend Neuro has disclosed Net Cash Flow across 7 years of filings, most recently posting -$2.0 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 439.1% year-over-year to -$2.0 million; the TTM figure through Apr 2026 stood at -$3.2 million (down 190.63% YoY), while the FY2026 annual figure was -$3.2 million, down 190.63% from the prior year.
• Net Cash Flow came in at -$2.0 million for Q2 2026 at Alzamend Neuro, down from -$1.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.9 million in Q4 2024 to a low of -$3.4 million in Q3 2023.
• Average Net Cash Flow over 5 years is -$709657.3, with a median of -$1.3 million recorded in 2023.
• Year-over-year, Net Cash Flow sank 5210.54% in 2022 and jumped 533.74% in 2025.
• Over 5 years, Net Cash Flow stood at -$2.3 million in 2022, then soared by 35.44% to -$1.5 million in 2023, then soared by 291.56% to $2.9 million in 2024, then slumped by 140.41% to -$1.2 million in 2025, then slumped by 70.94% to -$2.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$2.0 million in Q2 2026, -$1.7 million in Q1 2026, and -$1.2 million in Q4 2025.